



ANNUAL REPORT

2018



Board of Trustees

Nicola Amoroso
Marta Brime
Eleonor Creaturo
Fernando Delgado
Lola Manterola (Chair)
Nuria Marti
Diego Megia
Alvaro Portanet
Snigdha Singh

Contents

Message from the President and Director	2
Immunotherapy	4
La Paz Paediatric Unit	7
Haematology Unit for Translational Research	8
Brain Tumours in Children Project	9
Prostate Cancer Unit	10
Cris Grants	11
MLL Leukaemia in Children	12
Teenagers Room	13
Volunteers	15
Dinner at the Embassy	16
A Night for (R)Evolution	17
My SuperCris Challenge	18
Running Challenges	19
On Ya Bike	20
Corporate Fundraising	21
Cris Cancer France	22
Overview of Projects	23
Accounts	24

—Letter from the Chair—

Dear Cris supporter,

You are playing a vital role in helping us save lives.

Thanks to your help, 2018 has been a really successful year for Cris Cancer fundraising, increasing our total income by 30% from 2017. We've had a huge variety of donors: those who do challenges to raise funds, people who donate prizes to be auctioned and others that support us at our Annual Ball.

Regular donors are extremely precious to us as they allow Cris to undertake long term commitments to support our researchers. Corporate support has also increased substantially in 2018 through direct grants, corporate events and matching programmes.

All of the work Cris has done in 2018 has been possible thanks to a very qualified and committed group of volunteers, to whom we are extremely grateful. Thanks to them, Cris devotes more than 95% of funds directly to fund cancer research.

Cris Cancer is accelerating the pathway from laboratory research to new treatments for patients.

We are currently helping to fund 12 cancer research projects, half of which are oncology projects for children. Childrens' projects do not generally attract much funding; big corporations are not as interested in supporting them as fewer children have cancer.

Cris is committed to fund these projects so that children can benefit from all new discoveries. This is why in 2018 we inaugurated the Advanced Therapies Unit in Childhood Cancer at La Paz Hospital, where 10 children have been able to spend the Christmas period receiving the care they so desperately need.

In 2018, there has been an unprecedented success in the treatment of over 400 patients in the Hematology Unit at the 12 de Octubre Hospital as well as the development of clinical trials that include therapies as novel and incredible as the CAR-T.

Cris has a strong partnership with the Institute of Cancer Research (ICR) in the UK. We are proud to be able to fund some of their innovative research projects. We continue to support brain tumour research for children with cancer and are currently building the new Cris Immunotherapy group within the ICR.

By supporting us you are part of Cris' team, joining research scientists, clinicians, patients, family members and many others. Our aim is to provide scientists with resources to enable rapid progress in the race to heal and defeat cancer. Together we are strong.

Thank you for your support.



Lola Manterola, Cris President





1000+

people treated in clinical trials since 2013



October

opened the Advanced Therapies Children Unit at La Paz Hospital.



€2.5 million

co-funded projects at the Hospital 12 de Octubre with CRIS Spain.



£600,000

raised at our 7th Annual Ball.

— Immunotherapy —

CRIS has committed £1.4 million to The Institute of Cancer Research (ICR), London.

Cancer immunotherapy – involving treatments that harness the body's own immune system to destroy tumours – is currently one of the most exciting areas of dramatic progress in cancer research. CRIS has already played an important role in developing immunotherapy for patients.

CRIS wants to invest further in this important field of science, and so has committed £1.4 million to The Institute of Cancer Research (ICR), London, to ensure advances in cancer research benefit patients now and in the long-term. The funds will be used to support one of the three new

research teams formed to focus on immunotherapy. The ICR is the top academic cancer research centre in Europe. The immunotherapy team, led by Prof. Mel Greaves FRS, Prof. Raj Chopra and Prof. Alan Melcher, has an impressive track record (including discovering the function of the thymus and UL leader in the phase III trial of T-VEC, etc).

The CRIS funded project will focus on current immunotherapy limitations, finding ways to 'awaken' the immune response in unresponsive tumors and to identify predictor factors for immunotherapy. This enables the selection of the best treatment options for each patient.







£614k
expended in
charitable
activities

Paediatric Oncology for Advanced Therapies Unit at La Paz Hospital


This Advanced Therapies Unit is a multidisciplinary working group combining cutting-edge research, clinical trials, and the most advanced therapies to treat the most difficult childhood cancer cases in an ever more personalised manner.

Funded by Cris Cancer Foundation and Cris contra el Cáncer.

Located on the 8th floor of La Paz Maternity-Children's University Hospital in Madrid, this space consists of:

- 10 bedrooms
- 4 state-of-the-art isolation rooms for haematopoietic progenitor transplants
- Clinical trial area
- Treatment preparation area
- Specialised laboratory
- Working area for clinical trial investigators, clinicians and monitors.

In October 2018, after two years of construction, the unit was opened to the public. This unit includes an onco-hematologist pediatrician, a geneticist, several bioinformaticians, a cell therapy laboratory technician, a project manager, data manager, a medical writer and several pre-and post-doctoral researchers working side by side to improve oncological treatments.



6

clinical trials

15

children
treated since
October

250k
invested

Unit for Translational Research and Clinical Trials in Haematology

This unit combines clinical research on patients and laboratory research within haematology tumours at Hospital 12 de Octubre in Spain.

Funded by Cris Cancer Foundation and Cris contra el Cáncer.

The unit provides treatment to hospital patients and outpatients, and also implements clinical trials. Operation of this unit allows first-hand research of these tumours, which are currently, to a great extent, incurable.


Since the launch in 2013, more than 400 patients have benefitted from this project. The innovative treatments have been remarkably safe, and the toxicity very low. The research is very promising and we look forward to its further development.

130
clinical trials

150K
invested

since
2013

600
patients
benefitted



Joaquin Martinez Cris Scientific Director

Brain Tumours in Children Project at the ICR, London

This project works to identify genetic mutations in brain tumours that are characteristic of different cancer subtypes. This can help clinicians choose the most effective treatment.

Funded by Cris Cancer Foundation and Institute of Cancer Research.

This year, Professor Chris Jones and his team have been able to classify brain tumours based on the genetic alterations they observed through the analysis of 220 samples of tumour cells.

This vital work is why Cris Cancer are funding research in addition to a PHD student through the course of this project.

A key discovery this year was the identification of several genetic alterations in different patient groups. This will allow doctors to choose more suitable treatments.

The results will be published in 2019.

over
94k
invested



—Prostate Cancer Unit—

The prostate cancer unit is working to develop new treatments for prostate cancer in its most aggressive forms. The group is implementing a large number of clinical trials including several multi-centre trials, as well as smaller trials and preclinical investigation projects.

Funded by Cris Cancer Foundation and Cris contra el Cáncer.

In 2018, the PROREPAIR B clinical trial supplied important information about the gene mutation involved in DNA repair, and made significant advances in the treatment of patients with a mutated BRCA2 gene.

The study of this gene has been extremely important in treating prostate cancer, which doesn't respond to traditional treatments. 348 patients were involved in this clinical trial, and the project has received a number of awards and international grants.

348
patients tested

£50k
invested



— Cris Grants —

We are strongly committed to training medical and research personnel, with the goal of positioning ourselves as the global vanguard in cancer research and treatment.

Funded by Cris Cancer Foundation and Cris contra el Cáncer.

Thank you, for a second consecutive year, to one of our major donors, Goldman Sachs Gives, who donated £40,000 in support of grants for scientists & researchers. The funds were transferred to our grant programme in Spain in October.

These funds have been incredibly beneficial to our cause and we are grateful for the continued support of these organisations.

£40k
invested



— MLL Leukaemia in Children —

The goal of this project was to seek new treatment alternatives for MLL leukaemia by analysing samples. Analyses were performed on genetic mutations and other kinds of alterations affecting cell behaviour.

Funded by Cris Cancer Foundation and Cris contra el Cáncer.

In 2018, Dr Mireia Camós published an article as a result of her research in the prestigious publication, The British Journal of Haematology.

The article focussed on a type of protein named Histone Deacetylases (HDACS) with the hypothesis that pharmacologically targeting these proteins selectively would be a more effective way of tackling this type of leukaemia.

The results have been disclosed in a number of international congresses such as the “Biennial Childhood Leukaemia and Lymphoma Symposium” and the “European Haematology Association”.

£15k
invested



Mireia Camós Cris Researcher

— Teenagers Room at La Paz —

After the opening of the Immunotherapy unit in La Paz Hospital, we identified the necessity for a private room for teenagers.

Funded by Cris Cancer Foundation.

Thanks to an anonymous major donor, we were able to create a Teenagers Room to provide teenagers in the hospital their own personal space outside of their rooms. Besides giving them a communal space to meet, it provides them with an opportunity to meet other residents in similar situations.

£5.5k
invested





— Volunteers —

The Cris Cancer Foundation is built on the hard work of our volunteers. Without them, the success of 2018 would not be possible. It is thanks to their time, energy, enthusiasm and dedication that we have made significant achievements.

— Office and Events volunteers —

Our office and events volunteers are essential in promoting activities, attending weekly meetings, developing new ideas and getting involved in all the administration

work required in the day to day running of the office. Without these core pillars of the charity, the events wouldn't be the successes they are.



— Ball Committees —

Our Annual Ball is organised by two committees made up of volunteers. They plan the event, research and source prizes, and are involved in nearly every aspect of the making the Ball as fantastic as it always is. They're truly indispensable and we're always grateful for their time and commitment to Cris.

This year the Ball was a major success and it was all thanks to them!



— Dinner at the Embassy —

In order to develop the Major Donor programme, on the 20th of September we organised a dinner at the Spanish Embassy in London.

Thanks to the Spanish Ambassador of Spain in the UK, His Excellency Mr Carlos Bastarreche, for hosting this dinner. As part of the Major Donor programme, 40 guests were invited to share a lovely evening with the CEO of the ICR, Prof Paul Workman, and Prof Rajesh Chopra, Head of the Division of Cancer Therapeutics, to learn about immunotherapy and the new project that Cris Cancer Foundation is starting with the ICR, committing £1.4 million. We also had the pleasure of listening to cancer patient Matt Spence, who shared his immunotherapy success story.



The evening was absolutely delightful. The room in the embassy was awe inspiring, featuring the second biggest dining table in the UK, originally built for The Titanic. In the end, the final amount raised was £65,000. Thank you again to our generous donors.



£65k
raised

40
guests

— A Night for (R)Evolution —

The Annual Ball is our flagship fundraising event. Every year we focus on a theme for the night. 2018 was the year for the revolution in immunotherapy.

On the 10th of November, 2018, over 430 guests helped us raise a record-breaking £600,000 after hearing about the Immunotherapy project with the Institute of Cancer Research (ICR).

We are extremely grateful to our main sponsor R.J. O'Brien for their commitment to our mission and we also want to extend our thanks to Stacy Ciauri, Ximo Peris and Eduardo Marti for donating their creative expertise to produce the wonderful videos and slides. Thank you also to all the prize donors who made such an amazing night possible.

During the evening, guests had the unique opportunity to learn about immunotherapy from one of the top researchers in the ICR -

Prof Kevin Harrington, Joint Head of the Division of Radiotherapy and Imaging - as well as hearing the breath-taking story of cancer survivor, Matt Spence.

Diego Megia, president of Cris Contra el Cáncer presented the fantastic results we've facilitated in the Paediatric Oncology for Advanced Therapies unit at La Paz Hospital, that CRIS funded with the funds raised at the 2017 ball.

The success of the Ball is due to the tireless work of our two amazing fundraising committees, board of trustees, volunteers and the Cris Team.

over
500k net
proceeds



— My SuperCris Challenge —



Fundraising

2018 was the most successful fundraising year since Cris began. Our SuperCris supporters challenged themselves to a huge variety of tasks and events as part of the My SuperCris Challenge Campaign, from running a full marathon to selling crochet bags in the summer!

Since My SuperCris Challenge campaign was created in 2015, the funds raised and the number of participants have grown consistently. During this time, we have offered two main challenges: The Royal Parks Half Marathon and the AntiCancer Challenge.

— Community Fundraising —

£20k
raised

20
fundraisers

Community fundraising is essential for Cris, not only because of the funds raised but also for building awareness and visibility of our work.

This year our supporters have been involved in a wide variety of events to raise money for research, including a birthday party, selling goods, organising a summer concert, taking part in a family or school activity, helping facilitate a children's concert, organising a catwalk... and more!

— Anti Cancer Challenge —

£15k
raised

40 people
involved

This was created by Lola Manterola, president of Cris Cancer Foundation. The challenge is to eat healthily and form better habits, like regular exercise and eating plenty of fruit and vegetables. Together with nutritionist Cecilia Neri, we encourage participants to change their diet for a month to become aware of what they eat.

In May, 40 people took part in the challenge in the UK, and 21 in Spain. This is now known as the 'Beet' Cancer Challenge.

Running Challenges

Royal Parks Half Marathon



In October, 50 inspiring runners took part in the iconic half marathon in central London. Ranging from beginners to advanced runners, they all ran together to support our cause. Our amazing runners raised over £40,000, including a special group of 10 from the Bank of America Merrill Lynch who, together, raised over £10,000. Amongst the 16,000 runners who crossed the finish line were three Cris Trustees!

40k raised
55 runners

4th February World Cancer Day

On the 4th of February, World Cancer Day, 35 of us, including the president and her family, ran the coolest 10k in London wearing SuperCris shirts and raising awareness for cancer research.

35 participants
raising awareness



On Ya Bike



On Ya Bike is a virtual cycling race where teams or individuals cycle in the office to raise money for research against cancer.

Corporate Events

over **£70k** raised
200 fundraisers

On Ya Bike is an exciting virtual cycling race that Cris organised again in 2018 in various organisations. Since we launched this event three years ago, we have had various corporates get involved, including Barclays Bank, Google, Ferrovial and Santander Bank.

This year we completed two OnYaBikes in Barclays Bank and Santander, whose employees raised over £35,000, which was then matched by Barclays and Santander.



Corporate Fundraising

Thanks to corporate events and matching programmes as well as the support of new corporates, we've seen an increase in giving this year.

Corporate Collaboration

Companies such as Goldman Sachs, Balyasni Asset Management LP, Janus Henderson, Barclays, Tradeweb, Ako Capital, and Santander Bank, among others, have been a fantastic support to Cris by donating funds to our programmes.

over
£230k raised

Matching Programme Scheme

A lot of companies in the UK provide a matching programme wherein employees can request their donations be matched by the employers. The amount that was matched overall in 2018 was £28,000.

over
£28k raised



—Cris Cancer France—

Following the advice of experts, and after identifying great potential in France, Cris UK has supported the creation of a new branch in Paris.

Funded by Cris Cancer Foundation.



This new project will begin its own fundraising in 2019. Cris already has three volunteers who are French natives on board. To help support the first steps of CRIS Cancer France, CRIS Cancer UK has already transferred £10,000.

With these funds, Cris Cancer France registered the charity. They are expecting to launch the charity in the second term of 2019 and are confident that they will gather a great number of supporters.

Meanwhile, we have already identified a potential project in France, linked to Professor Chris Jones and his research at the ICR which will be funded by Cris.

Children's Oncology Projects

**MLL
Leukemia**

**Brain
Tumours
(ICR)**

**Ewing
Sarcoma**

**Natural
Killers**

**Paediatric
Oncology
Unit**

**Prostate
Cancer**

**Lydia
Project**

cris
cancer foundation

**Ovarian
Cancer**

**Breast
Cancer**

**Immuno-
therapy
(ICR)**

Adult Oncology Projects

**Immuno-
therapy
(Unit)**

**Haemato-
logical
(Unit)**

Projects Overview 2018

Income and Expenditure 2018

	2018			2017
	Unrestricted	Restricted	Total	Total
Incoming resources	£	£	£	£
Income from:				
Donations and legacies	453,013	55,000	508,013	298,436
Other trading activities	627,758	-	627,758	510,393
Investments	1,366	-	1,366	1,601
Total incoming resources	1,082,137	55,000	1,137,137	810,430
Expenditure on				
Raising funds:				
Fundraising events	116,255	-	116,255	89,736
Charitable activities:				
Donations made to research	465,500	55,000	520,500	835,331
Overheads	42,693	0	42,693	
Total Expenditure	508,193	55,000	563,193	925,067
Net movement in funds	457,690	-	457,690	-114,637
Reconciliation of funds:				
Total funds brought forward	262,100	-	262,100	376,737
Total funds carried forward	719,790	-	719,790	262,100

£1.1m
overall income
in 2018

<5%
overheads
in 2018

CRIS CANCER FOUNDATION
A COMPANY LIMITED BY GUARANTEE
(CHARITY NO. 1140193)

ANNUAL REPORT AND FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 DECEMBER 2018

The financial statements comply with the Charities Act 2011, the Companies Act 2006, the Memorandum and Articles of Association, and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015).



Cancer is the UK's biggest killer. Whilst research has helped make significant progress against the disease in recent decades, some cancer types are still leading the list of deadliest diseases.



Cris Cancer Foundation
43 Sussex Street
London
SW1 V4RJ

Reg. Charity No. 1140193
T: +44(0)2076309410
E: info@criscancer.org.uk
[@criscanceruk](https://www.criscanceruk.org)